NPS Pharmaceuticals, Inc. (NPSP): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report


We are downgrading NPS Pharma to Underperform following the lackluster performance of the company in the first quarter of 2014. The company reported a wider-than-expected loss in the quarter as revenues fell short of expectations. NPS Pharma trimmed its outlook for Gattex (its sole marketed product) net sales in 2014 based on sluggish sales in January and February. The company now expects net sales in the range of $100 million to $110 million (old guidance: $110 million to $120 million). Earnings estimates for 2014 as well as 2015 are on the downswing. Given the disappointing situation, we advise investors to get rid of the stock. Our target price is $30.00 per share.


Headquartered in Bedminster, N.J. and founded in 1986, NPS Pharmaceuticals, Inc. is a biopharmaceutical company which focuses on developing and commercializing therapies for treating patients suffering from rare diseases.

NPS Pharma's sole marketed product is Gattex (teduglutide). The drug is available in the U.S. (since Feb 2013) as a subcutaneous injection for treating adults with short bowel syndrome (SBS), dependent on parenteral support.

Gattex was cleared in the EU in 2012 (European trade name: Revestive). NPS Pharma expects to commence pricing/reimbursement discussions with authorities in some EU countries during the year.

NPS Pharma expects to add another product Natpara (rhPTH [1-84]) to its portfolio later in the year. The company is looking to get Natpara, which has been granted orphan drug status in the U.S. and EU, approved for treating hypoparathyroidism. The candidate is currently under review in the U.S. A decision from the FDA on Natpara is expected by Oct 24, 2014. In 2013, NPS Pharma regained the worldwide rights to Revestive and rhPTH 1-84 from Takeda. Takeda marketed rhPTH 1-84 under the brand name Preotact for the treatment of osteoporosis in some of its licensed territories.

NPS Pharma's pipeline also includes NPSP795 (autosomal dominant hypocalcemia). NPS Pharma intends to make significant efforts to advance the development of the candidate during the course of the year.

Revenues in 2013 climbed 19.1% to $155.6 million

NPS Pharmaceuticals, Inc. (NPSP): Read the Full Research Report
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

NPS PHARMA INC (NPSP): Free Stock Analysis Report

To read this article on click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: Investing , Stocks

Referenced Stocks: SBS , NPSP

More from

Related Videos




Most Active by Volume

  • $16.20 ▼ 0.80%
  • $102.13 ▲ 1.23%
  • $3.59 ▲ 0.84%
  • $19.21 ▲ 5.38%
  • $74.63 ▼ 1.75%
  • $48.06 ▼ 0.23%
  • $38.18 ▲ 1.03%
  • $11.20 ▲ 3.70%
As of 8/27/2014, 04:02 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by